Megan Othus

11.2k total citations · 1 hit paper
252 papers, 5.9k citations indexed

About

Megan Othus is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Megan Othus has authored 252 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Hematology, 92 papers in Oncology and 60 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Megan Othus's work include Acute Myeloid Leukemia Research (137 papers), Acute Lymphoblastic Leukemia research (55 papers) and Hematopoietic Stem Cell Transplantation (38 papers). Megan Othus is often cited by papers focused on Acute Myeloid Leukemia Research (137 papers), Acute Lymphoblastic Leukemia research (55 papers) and Hematopoietic Stem Cell Transplantation (38 papers). Megan Othus collaborates with scholars based in United States, South Africa and France. Megan Othus's co-authors include Frederick R. Appelbaum, Elihu H. Estey, Roland B. Walter, Brent L. Wood, Jennifer D. Allen, Jerald P. Radich, Harry P. Erba, Rachel C. Shelton, Min Fang and Stephen H. Petersdorf and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Megan Othus

225 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

2014 479 citations Frederick R. Appelbaum, Stephen H. Petersdorf et al. profile →

Peers

Countries citing papers authored by Megan Othus

Since Specialization

Citations

This map shows the geographic impact of Megan Othus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Othus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Othus more than expected).

Fields of papers citing papers by Megan Othus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Othus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Othus. The network helps show where Megan Othus may publish in the future.

Co-authorship network of co-authors of Megan Othus

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Othus. A scholar is included among the top collaborators of Megan Othus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Othus. Megan Othus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort 2025 ·Cancer Communications ·Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, (unknown), (unknown), Sajeve Thomas, William R. Robinson, Hye Sung Kim, (unknown), Christine M. McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock	0
2	Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma 2025 ·npj Precision Oncology ·Sandip Pravin Patel, (unknown), Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers, Adrienne I. Victor, Adedayo A. Onitilo, (unknown), Naoko Takebe, (unknown), Christine M. McLeod, (unknown), Elad Sharon, Megan Othus, (unknown), Charles D. Blanke, Razelle Kurzrock	1
3	Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors 2025 ·JNCI Journal of the National Cancer Institute ·Yuhan Huang, Marilyn L. Kwan, Susan R. Heckbert, (unknown), Megan Othus, Cecile A. Laurent, Janise M. Roh, Eileen Rillamas‐Sun, Valerie S. Lee, Tatjana Kolevska, Richard K. Cheng, (unknown), Mai N. Nguyen‐Huynh, Dawn L. Hershman, Lawrence H. Kushi, Heather Greenlee	1
4	Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML 2024 ·American Journal of Hematology ·Corentin Orvain, (unknown), Megan Othus, Eduardo Rodríguez‐Arbolí, Filippo Milano, (unknown), Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter	4
5	Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches 2024 ·Journal of Clinical Oncology ·Megan Othus, Boris Freidlin, Edward L. Korn	2
6	Abstract CT262: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: sarcomatoid carcinoma of lung (cohort 11) 2024 ·Cancer Research ·Young Kwang Chae, Megan Othus, Sandip Pravin Patel, (unknown), (unknown), Jeremy Cetnar, (unknown), Anna Moseley, (unknown), Hye Sung Kim, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock	0
7	Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents 2023 ·Leukemia & lymphoma ·(unknown), Megan Othus, (unknown), (unknown), Anna B. Halpern, Jacob Appelbaum, Paul C. Hendrie, Roland B. Walter, Elihu H. Estey, Mary‐Elizabeth M. Percival	1
8	Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia 2023 ·Journal of Clinical Oncology ·Jason E. Farrar, Jenny L. Smith, Megan Othus, Benjamin J. Huang, Yicheng Wang, Rhonda E. Ries, (unknown), Era L. Pogosova‐Agadjanyan, Sneha Challa, Amanda R. Leonti, Timothy I. Shaw, Timothy J. Triche, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Xiaotu Ma, Derek L. Stirewalt, Todd A. Alonzo, Soheil Meshinchi	13
9	RECeUS: Ratio estimation of censored uncured subjects, a different approach for assessing cure model appropriateness in studies with long‐term survivors 2022 ·Statistics in Medicine ·(unknown), Megan Othus	0
10	Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms 2022 ·Leukemia ·(unknown), Megan Othus, (unknown), (unknown), Mohamed L. Sorror, Anna B. Halpern, Jacob Appelbaum, Paul C. Hendrie, Roland B. Walter, Elihu H. Estey, Mary‐Elizabeth M. Percival	4
11	A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations) 2021 ·Blood ·Anjali S. Advani, Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron T. Gerds, Susan O’Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba	9
12	Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy 2021 ·Leukemia & lymphoma ·Anna B. Halpern, Megan Othus, Nicholas P. Howard, Paul C. Hendrie, Mary‐Elizabeth M. Percival, (unknown), Verna Welch, Elihu H. Estey, Roland B. Walter	2
13	Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML 2020 ·Cancer Medicine ·Mohamed L. Sorror, (unknown), Megan Othus, (unknown), Jennifer E. Nyland, Mary‐Elizabeth M. Percival, Pamela S. Becker, Frederick R. Appelbaum, Elihu H. Estey	1
14	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial 2019 ·Blood ·Annette E. Hay, Sarit Assouline, Roland B. Walter, Richard F. Little, Anna Moseley, (unknown), Annie Im, James M. Foran, Jerald P. Radich, Min Fang, Megan Othus, Harry P. Erba, Laura C. Michaelis	7
15	Prognostic Significance of NPM1 Mutations in the Absence of FLT3 –Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report 2015 ·Journal of Clinical Oncology ·Fabiana Ostronoff, Megan Othus, (unknown), Elihu H. Estey, Frederick R. Appelbaum, Anna Evans, John E. Godwin, Amanda Gilkes, Kenneth J. Kopecky, Alan K. Burnett, Alan F. List, Min Fang, Vivian G. Oehler, Stephen H. Petersdorf, Era L. Pogosova‐Agadjanyan, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt	96
16	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission? 2015 ·Journal of Clinical Oncology ·Daisuke Araki, Brent L. Wood, Megan Othus, Jerald P. Radich, Anna B. Halpern, Yi Zhou, Marco Mielcarek, Elihu H. Estey, Frederick R. Appelbaum, Roland B. Walter	258
17	Cure Models as a Useful Statistical Tool for Analyzing Survival 2012 ·Clinical Cancer Research ·Megan Othus, Bart Barlogie, Michael LeBlanc, John J. Crowley	151
18	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment 2011 ·Journal of Clinical Oncology ·Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jörge E. Cortes, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey	244
19	Change-point cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients 2011 ·Journal of Applied Statistics ·Megan Othus, Yi Li, Ram C. Tiwari	11
20	A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions 2008 ·Cancer Prevention Research ·Lori J. Wirth, Jeffrey F. Krane, Yi Li, Megan Othus, Amy E. Moran, (unknown), Charles M. Norris, Laura A. Goguen, Marshall R. Posner, Robert I. Haddad, Monica M. Bertagnolli	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact